Phyox2 data back Dicerna’s nedosiran in just one type of primary hyperoxaluria, where Alnylam already has an 18-month head start.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.